• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

按发育阶段和临床表现的 ADHD 治疗方法。

Therapeutic Approaches for ADHD by Developmental Stage and Clinical Presentation.

机构信息

Unidad de Atención en Neurociencias, Departamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.

Instituto de Neurociencias Traslacionales, Departamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.

出版信息

Int J Environ Res Public Health. 2022 Oct 8;19(19):12880. doi: 10.3390/ijerph191912880.

DOI:10.3390/ijerph191912880
PMID:36232180
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9566361/
Abstract

Attention Deficit Hyperactivity Disorder is a neurodevelopmental disorder with three presentations: inattentive, hyperactive/impulsive and combined. These may represent an independent disease entity. Therefore, the therapeutic approach must be focused on their neurobiological, psychological and social characteristics. To date, there is no comprehensive analysis of the efficacy of different treatments for each presentation of ADHD and each stage of development. This is as narrative overview of scientific papers that summarize the most recent findings and identify the most effective pharmacological and psychosocial treatments by ADHD presentation and age range. Evidence suggests that methylphenidate is the safest and most effective drug for the clinical management of children, adolescents and adults. Atomoxetine is effective in preschoolers and maintains similar efficacy to methylphenidate in adults, whereas guanfacine has proven to be an effective monotherapy for adults and is a worthy adjuvant for the management of cognitive symptoms. The psychosocial treatments with the best results in preschoolers are behavioral interventions that include training of primary caregivers. In adolescents, the combination of cognitive and cognitive-behavioral therapies has shown the best results, whereas cognitive-behavioral interventions are the most effective in adults. Pharmacological and psychosocial treatments must be adjusted to the ADHD presentation and its neurocognitive characteristics through the patient's development.

摘要

注意缺陷多动障碍是一种神经发育障碍,有三种表现形式:注意力不集中、多动/冲动和混合型。这些可能代表一个独立的疾病实体。因此,治疗方法必须针对其神经生物学、心理和社会特征。迄今为止,尚无针对 ADHD 每种表现形式和每个发育阶段的不同治疗方法的综合分析。这是对科学论文的叙述性综述,总结了 ADHD 表现形式和年龄范围的最有效药物和心理社会治疗方法。有证据表明,哌甲酯是儿童、青少年和成人临床管理中最安全、最有效的药物。阿托西汀对学龄前儿童有效,且在成人中的疗效与哌甲酯相似,而胍法辛已被证明是成人有效单药治疗方法,也是管理认知症状的一种值得选择的辅助药物。对学龄前儿童最有效的心理社会治疗方法是包括对主要照顾者进行培训的行为干预。在青少年中,认知和认知行为疗法的结合显示出最好的效果,而认知行为干预在成人中最有效。药物和心理社会治疗必须根据患者的发展情况,根据 ADHD 的表现及其神经认知特征进行调整。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd2e/9566361/69d32ccaa580/ijerph-19-12880-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd2e/9566361/59f44934f0f4/ijerph-19-12880-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd2e/9566361/69d32ccaa580/ijerph-19-12880-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd2e/9566361/59f44934f0f4/ijerph-19-12880-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd2e/9566361/69d32ccaa580/ijerph-19-12880-g002.jpg

相似文献

1
Therapeutic Approaches for ADHD by Developmental Stage and Clinical Presentation.按发育阶段和临床表现的 ADHD 治疗方法。
Int J Environ Res Public Health. 2022 Oct 8;19(19):12880. doi: 10.3390/ijerph191912880.
2
Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.青少年注意缺陷多动障碍的治疗:系统评价。
JAMA. 2016 May 10;315(18):1997-2008. doi: 10.1001/jama.2016.5453.
3
Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.从业者综述:自闭症谱系障碍儿童和青少年注意缺陷/多动障碍症状的药物治疗:系统评价和荟萃分析。
J Child Psychol Psychiatry. 2021 Jun;62(6):680-700. doi: 10.1111/jcpp.13305. Epub 2020 Aug 26.
4
Pharmacotherapy for ADHD in children and adolescents: A summary and overview of different European guidelines.儿童和青少年注意缺陷多动障碍的药物治疗:不同欧洲指南的总结和概述。
Eur J Pediatr. 2024 Mar;183(3):1047-1056. doi: 10.1007/s00431-023-05370-w. Epub 2023 Dec 14.
5
An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.一项关于哌甲酯和托莫西汀治疗注意缺陷/多动障碍儿童的开放标签随机试验。
J Child Adolesc Psychopharmacol. 2015 Sep;25(7):566-73. doi: 10.1089/cap.2015.0035. Epub 2015 Jul 29.
6
[Attention deficit hyperactivity disorder in childhood and adolescence : Current state of research].[儿童和青少年注意力缺陷多动障碍:研究现状]
Nervenarzt. 2020 Jul;91(7):599-603. doi: 10.1007/s00115-020-00904-1.
7
Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder.哌甲酯与托莫西汀对注意缺陷/多动障碍青少年情绪和行为问题的疗效比较
J Child Adolesc Psychopharmacol. 2019 Feb;29(1):9-19. doi: 10.1089/cap.2018.0076. Epub 2018 Nov 17.
8
Comparative Efficacy of Methylphenidate and Atomoxetine on Social Adjustment in Youths with Attention-Deficit/Hyperactivity Disorder.哌甲酯与托莫西汀治疗青少年注意缺陷多动障碍的社会功能比较
J Child Adolesc Psychopharmacol. 2020 Apr;30(3):148-158. doi: 10.1089/cap.2019.0139. Epub 2019 Nov 27.
9
Evidence-based pharmacological treatment options for ADHD in children and adolescents.儿童和青少年注意缺陷多动障碍的循证药理学治疗选择。
Pharmacol Ther. 2022 Feb;230:107940. doi: 10.1016/j.pharmthera.2021.107940. Epub 2021 Jun 23.
10
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.注意缺陷多动障碍:儿科药物治疗的最新进展。
Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000.

引用本文的文献

1
Perspectives on Physical Activity and Learning from Children With and Without ADHD.对患有和未患有注意力缺陷多动障碍儿童的体育活动与学习的看法。
Sports (Basel). 2025 Jul 22;13(8):240. doi: 10.3390/sports13080240.
2
Individual Differences in the Neurocognitive Effect of Movement During Executive Functioning in Children with ADHD: Impact of Subtype, Severity, and Gender.多动症儿童执行功能期间运动的神经认知效应的个体差异:亚型、严重程度和性别的影响。
Brain Sci. 2025 Jun 9;15(6):623. doi: 10.3390/brainsci15060623.
3
Growing evidence of pharmacotherapy effectiveness in managing attention-deficit/hyperactivity disorder in young children with or without autism spectrum disorder: a minireview.

本文引用的文献

1
Efficacy of Group Cognitive Behavior Therapy Targeting Time Management for Adults with Attention Deficit/Hyperactivity Disorder in Japan: A Randomized Control Pilot Trial.日本针对注意力缺陷/多动障碍成年人的团体认知行为疗法在时间管理方面的疗效:一项随机对照试验。
J Atten Disord. 2022 Feb;26(3):377-390. doi: 10.1177/1087054720986939. Epub 2021 Jan 20.
2
Pharmacologic Treatment of Attention Deficit-Hyperactivity Disorder.注意缺陷多动障碍的药物治疗
N Engl J Med. 2020 Sep 10;383(11):1050-1056. doi: 10.1056/NEJMra1917069.
3
Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
越来越多的证据表明药物疗法在治疗患有或未患有自闭症谱系障碍的幼儿注意力缺陷/多动障碍方面的有效性:一篇综述。
Front Psychiatry. 2024 Jun 24;15:1408876. doi: 10.3389/fpsyt.2024.1408876. eCollection 2024.
4
Atomoxetine Treatment of Attention Deficit/Hyperactivity Disorder Symptoms in 3-6-Year-Old Children with Autism Spectrum Disorder: A Retrospective Cohort Study.托莫西汀治疗3至6岁自闭症谱系障碍儿童注意力缺陷/多动障碍症状:一项回顾性队列研究
Children (Basel). 2024 Jan 26;11(2):163. doi: 10.3390/children11020163.
5
Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays.发现胍法辛作为一种新型TAAR1激动剂:通过分子模拟研究和生物学试验的联合策略。
Pharmaceuticals (Basel). 2023 Nov 20;16(11):1632. doi: 10.3390/ph16111632.
6
Investigation of the feasibility and acceptability of a school-based intervention for children with traits of ADHD: protocol for an iterative case-series study.基于学校的 ADHD 特质儿童干预措施的可行性和可接受性研究:一项迭代病例系列研究的方案。
BMJ Open. 2023 Feb 14;13(2):e065176. doi: 10.1136/bmjopen-2022-065176.
胍法辛缓释剂治疗成人注意缺陷多动障碍的疗效和安全性:一项随机、双盲、安慰剂对照研究的结果。
J Clin Psychiatry. 2020 Apr 14;81(3):19m12979. doi: 10.4088/JCP.19m12979.
4
Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses.哌醋甲酯治疗注意缺陷多动障碍的平行和交叉随机临床试验的方法学优缺点:系统评价和荟萃分析。
BMJ Open. 2019 Mar 30;9(3):e026478. doi: 10.1136/bmjopen-2018-026478.
5
Guanfacine monotherapy for ADHD/ASD comorbid with Tourette syndrome: a case report.用于治疗合并抽动秽语综合征的注意力缺陷多动障碍/自闭症谱系障碍的胍法辛单一疗法:一例报告
Ann Gen Psychiatry. 2019 Mar 11;18:2. doi: 10.1186/s12991-019-0226-6. eCollection 2019.
6
Atomoxetine improves attentional orienting in a predictive context.阿托西汀改善预测情境中的注意力定向。
Neuropharmacology. 2019 May 15;150:59-69. doi: 10.1016/j.neuropharm.2019.03.012. Epub 2019 Mar 12.
7
Effects of acute and sub-chronic administrations of guanfacine on catecholaminergic transmissions in the orbitofrontal cortex.急性和亚慢性胍法辛给药对眶额皮质儿茶酚胺能传递的影响。
Neuropharmacology. 2019 Sep 15;156:107547. doi: 10.1016/j.neuropharm.2019.02.029. Epub 2019 Feb 22.
8
Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers.速释与缓释胍法辛在成年每日吸烟者中的药代动力学和药效学
J Clin Psychopharmacol. 2019 Mar/Apr;39(2):124-128. doi: 10.1097/JCP.0000000000001004.
9
Differential effects of ADHD medications on impulsive action in the mouse 5-choice serial reaction time task.ADHD 药物对小鼠 5 选择连续反应时任务中冲动行为的差异影响。
Eur J Pharmacol. 2019 Mar 15;847:123-129. doi: 10.1016/j.ejphar.2019.01.038. Epub 2019 Jan 25.
10
Chronic methylphenidate preferentially alters catecholamine protein targets in the parietal cortex and ventral striatum.慢性哌醋甲酯优先改变顶叶皮层和腹侧纹状体中的儿茶酚胺蛋白靶标。
Neurochem Int. 2019 Mar;124:193-199. doi: 10.1016/j.neuint.2019.01.016. Epub 2019 Jan 17.